Education
About Us
Working with TipRanks
Follow Us
Bio-Techne (TECH)
NASDAQ:TECH
Earnings Data
Report Date
May 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
0.54Last Year’s EPS
0.56Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call balanced encouraging execution and strategic progress against clear near-term headwinds. Positive drivers include 10% adjusted EPS growth, ~100 bps operating margin expansion, strong instrument bookings (Comet, LEO), product innovation (Ella assays), geographic momentum in China and APAC, Wilson Wolf growth, and solid cash generation and balance-sheet metrics. Offsetting these positives were flat consolidated revenue, material short‑term order timing impacts from two large cell therapy customers (causing steep GMP reagent declines), gross margin compression from unfavorable product/customer mix, and continued weakness in emerging biotech and parts of academia. Management expects the cell therapy timing headwinds to moderate through Q4 and underlying business trends to improve, supporting a constructive medium-term outlook.Company Guidance
Adjusted EPS Growth
Adjusted EPS of $0.46, up 10% year-over-year (foreign exchange contributed ~$0.04 of the beat). GAAP EPS was $0.24, up from $0.22 in the prior year period.
Operating Margin Expansion and Expense Discipline
Adjusted operating margin expanded ~100 basis points year-over-year to 31.1% driven by productivity, cost management and the Exosome Diagnostics divestiture. Adjusted SG&A improved to 29.6% of revenue (down 240 bps) and R&D was 7.8% (down from 8.5%).
Revenue Context — Underlying Growth Excluding Large Cell Therapy Customers
Total revenue was $295.9M, flat year-over-year on both reported and organic bases. After excluding order-timing impacts from two largest cell therapy customers, organic growth was ~4% for the quarter. Foreign FX contributed a ~2% tailwind while businesses held for sale created a ~2% headwind.
Strength in Proteomic Instruments and Product Innovation
ProteinSimple instrument sales grew upper single digits in Q2 despite a constrained capital environment. Notable innovation includes ultra-sensitive Ella assays (2-5x sensitivity improvement) and strong demand for LEO (next-gen Simple Western) with recent fluorescence multiplexing enhancements.
Spatial Biology Momentum and Comet Bookings
Bookings for the automated Comet platform accelerated meaningfully — nearly 40% growth in bookings (second consecutive strong quarter). RNAscope diagnostic adoption grew >20% for the quarter and first half, while RNAscope research sales grew low single digits.
Diagnostics Growth and New Molecular Kits
Diagnostics delivered high single-digit growth driven by clinical controls and molecular diagnostic kits, including adoption of ESL One exosome-based mutation kit and Amplidex Carrier Screening Plus.
Geographic Strength — China and APAC
China achieved mid-single-digit growth (third consecutive quarter of growth). APAC (ex-China) grew nearly 20%; adjusted for cell therapy order timing, the Americas would have grown low single digits.
Wilson Wolf and Organoid Momentum
Wilson Wolf (20% ownership) delivered 20% organic revenue growth in the quarter and upper-teens TTM growth; Bio-Techne expects to complete the acquisition by end of calendar 2027. Organoid-related portfolio is a ~ $50M run-rate business and the company launched Culturex Synthetic Hydrogel to support non-animal organoid workflows.
Strong Cash Generation and Balance Sheet
Generated $82.4M in operating cash flow in Q2 with $5.9M in net capex. Ended quarter with $172.9M cash and bank debt of $260M (down $40M sequentially); leverage ratio well below 1x EBITDA. Returned $12.5M to shareholders via dividends.
TECH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TECH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 04, 2026 | $64.63 | $68.67 | +6.25% |
Nov 05, 2025 | $61.10 | $59.94 | -1.90% |
Aug 06, 2025 | $54.56 | $49.80 | -8.73% |
May 07, 2025 | $47.57 | $48.60 | +2.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bio-Techne (TECH) report earnings?
Bio-Techne (TECH) is schdueled to report earning on May 06, 2026, Before Open (Confirmed).
What is Bio-Techne (TECH) earnings time?
Bio-Techne (TECH) earnings time is at May 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TECH EPS forecast?
TECH EPS forecast for the fiscal quarter 2026 (Q3) is 0.54.